FELIQS closes $10 million Series A including extension
The round supports development of FLQ-101 for retinopathy of prematurity.
FELIQS announced on 3 October 2025 that it had closed a $10 million Series A, including an extension. The total includes the $9 million first close announced in July.
The July financing was co-led by Beyond Next Ventures and an unnamed major American pharmaceutical company. Japan Science and Technology Agency, Mitsubishi UFJ Capital, Keio Innovation Initiative and FFG Venture Business Partners also participated in that first close. The October announcement did not identify separate extension participants.
The Japanese biotechnology company is advancing FLQ-101, an investigational small-molecule treatment being developed to prevent retinopathy of prematurity.
Use of funds
Clinical development of FLQ-101 for retinopathy of prematurity